ter 286 has been researched along with erlotinib hydrochloride in 1 studies
| Studies (ter 286) | Trials (ter 286) | Recent Studies (post-2010) (ter 286) | Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) |
|---|---|---|---|---|---|
| 21 | 7 | 1 | 4,353 | 786 | 3,033 |
| Protein | Taxonomy | ter 286 (IC50) | erlotinib hydrochloride (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1683 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.705 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|
1 review(s) available for ter 286 and erlotinib hydrochloride
| Article | Year |
|---|---|
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |